519 related articles for article (PubMed ID: 20351256)
1. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.
Shi F; Telesco SE; Liu Y; Radhakrishnan R; Lemmon MA
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7692-7. PubMed ID: 20351256
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
3. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
4. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.
Littlefield P; Liu L; Mysore V; Shan Y; Shaw DE; Jura N
Sci Signal; 2014 Dec; 7(354):ra114. PubMed ID: 25468994
[TBL] [Abstract][Full Text] [Related]
5. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
6. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
Jura N; Shan Y; Cao X; Shaw DE; Kuriyan J
Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21608-13. PubMed ID: 20007378
[TBL] [Abstract][Full Text] [Related]
7. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
8. A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network.
Telesco SE; Shih AJ; Jia F; Radhakrishnan R
Mol Biosyst; 2011 Jun; 7(6):2066-80. PubMed ID: 21509365
[TBL] [Abstract][Full Text] [Related]
9. Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.
Fan YX; Wong L; Ding J; Spiridonov NA; Johnson RC; Johnson GR
J Biol Chem; 2008 Jan; 283(3):1588-1596. PubMed ID: 18039657
[TBL] [Abstract][Full Text] [Related]
10. P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells.
Ratchford AM; Baker OJ; Camden JM; Rikka S; Petris MJ; Seye CI; Erb L; Weisman GA
J Biol Chem; 2010 Mar; 285(10):7545-55. PubMed ID: 20064929
[TBL] [Abstract][Full Text] [Related]
11. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
[TBL] [Abstract][Full Text] [Related]
12. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T; Benjaminsen RV; Sonne-Hansen K; Sorensen BS; Nexo E; Laenkholm AV; Rasmussen LM; Riese DJ; de Cremoux P; Stenvang J; Lykkesfeldt AE
Breast Cancer Res Treat; 2009 Mar; 114(2):263-75. PubMed ID: 18409071
[TBL] [Abstract][Full Text] [Related]
13. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration.
Lee S; Greenlee EB; Amick JR; Ligon GF; Lillquist JS; Natoli EJ; Hadari Y; Alvarado D; Schlessinger J
Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13225-30. PubMed ID: 26460020
[TBL] [Abstract][Full Text] [Related]
15. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
16. Targeting of erbB3 receptor to overcome resistance in cancer treatment.
Ma J; Lyu H; Huang J; Liu B
Mol Cancer; 2014 May; 13():105. PubMed ID: 24886126
[TBL] [Abstract][Full Text] [Related]
17. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
18. RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.
Littlefield P; Moasser MM; Jura N
Chem Biol; 2014 Apr; 21(4):453-458. PubMed ID: 24656791
[TBL] [Abstract][Full Text] [Related]
19. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
Stern DF
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
[TBL] [Abstract][Full Text] [Related]
20. Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation.
Kancha RK; von Bubnoff N; Duyster J
Cell Commun Signal; 2013 Jun; 11():39. PubMed ID: 23758840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]